“Weight-loss drugs not covered”? The wording decides your next move.
You are not alone in this: a 2026 JAMA study of more than 2 million prescription attempts found GLP-1 weight-loss therapies were initially rejected at the pharmacy about 85% of the time — the highest rate of any drug class studied. And coverage keeps shrinking: from 2025 to 2026, roughly 12 million people were on plans that dropped Wegovy coverage, and about 12 million were on plans that dropped Zepbound.
But “not covered” is not one problem — it is two very different ones, and each has a different answer. Upload your denial letter and Lysco identifies which one you have, whether a real path exists, and drafts the appeal if it does. Your first read is free — and if the case is weak, the free read says so.
Free to see exactly what your denial says and whether a path exists. $9 to unlock the full appeal — only if you choose to proceed. No subscription.
The distinction that decides everything
Plan exclusion or “not medically necessary”? Read the letter first.
Two denials that feel identical are attacked completely differently. Before anything else, find the exact reason your letter cites.
A plan-design exclusion
The letter says something like “weight-management drugs are excluded under your plan,” “not a covered benefit,” or “benefit exclusion” — often pointing to the plan document or formulary rather than your medical record. The plan is saying it never bought this benefit for anyone. Arguing that you personally need the drug usually doesn’t move it. The real attacks are a formulary-exception request or the covered-indication pivot below.
A medical-necessity denial
The letter says “not medically necessary for you,” “clinical criteria not met,” or cites prior-authorization requirements. This one is about your documentation, not the plan’s design — and it is the more appealable kind. A documentation appeal compares the plan’s own written criteria against your chart and fills the gaps the reviewer flagged. More than 90% of commercial plans require prior authorization for GLP-1 weight-loss drugs, so paperwork-driven denials like this are common. Deadlines are real: internal appeals typically allow 180 days for commercial and ACA plans.
If the exclusion cited a formulary, not the benefit design: marketplace and other essential-health-benefit plans must decide a standard formulary-exception request within 72 hours (24 hours if expedited) under 45 CFR 156.122 — and if the exception is denied, that denial can go to independent external review. More than 30 states also have step-therapy override laws — check your state insurance department.
The covered-indication pivot
A “weight loss” exclusion doesn’t decide a different diagnosis
These medicines carry more than one FDA label. A plan that excludes weight-management use may still cover the same molecule under a different, documented indication. Three documented conditions map to separately labeled products:
Type 2 diabetes
Ozempic and Mounjaro are FDA-labeled for Type 2 diabetes. Ozempic and Wegovy are both semaglutide; Zepbound and Mounjaro are both tirzepatide — same molecules, different labels. If your chart documents Type 2 diabetes and you meet the label criteria and your prescriber documents it, the claim can run under the diabetes label instead of the excluded weight-loss one.
Established cardiovascular disease
In March 2024 the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight. If you meet the label criteria and your prescriber documents it, the request can be framed as cardiovascular risk reduction, not weight loss.
Moderate-to-severe obstructive sleep apnea
In December 2024 the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. A sleep-study diagnosis on file changes what the claim is about — if you meet the label criteria and your prescriber documents it.
The honest caveat: the pivot only exists if the condition is real, documented, and on the label. Whether any indication applies to you is a decision for you and your doctor — Lysco is informational only and never prescribes or recommends a drug. If your records support none of these, a pure design exclusion is a genuinely weak case, and the free first read will tell you that instead of dressing it up.
Employer plans
“Our plan just doesn’t cover it” — the employer-plan version
Many employer plans exclude weight-loss drugs by plan design, and self-funded employer plans set their own benefits — the employer, not a state mandate, decides what is in the plan document. That makes a written exclusion hard to appeal head-on.
But the exclusion only covers what it says. A plan-design exclusion of weight-loss use does not decide a claim submitted under a separate covered indication — Type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea, where your records and the label support it. Employer plans also owe you the plan documents and claim file on request. See the ERISA employer-plan appeal guide.
Government programs, honestly
Medicare and Medicaid: what’s actually true in 2026
Medicare: excluded by statute, with one narrow exception
Medicare Part D and Medicare Advantage cannot cover GLP-1s for weight loss — weight-loss drugs are excluded from Part D by statute. No appeal changes that. The narrow exception is the Medicare GLP-1 Bridge, a short-term CMS demonstration running July 1, 2026 through December 31, 2027: eligible Part D beneficiaries can get weight-management GLP-1s for about $50 a month. It excludes people with Type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH (those diagnoses have other coverage pathways), and it operates outside the normal Part D flow — it is not blanket Medicare coverage. Where Part D appeals do apply, deadlines can be as short as 60 days.
Medicaid: four states ended weight-loss coverage in January 2026
Effective January 1, 2026, Pennsylvania, California, New Hampshire, and South Carolina ended Medicaid coverage of GLP-1s for weight loss — taking the states covering obesity from 16 to 13. Type 2 diabetes and other approved indications are still covered with prior authorization, which makes the covered-indication pivot above especially relevant if you are on Medicaid in one of those states.
Build the record
What to ask your prescriber to document
The denial letter itself — its exact wording tells you whether you face an exclusion or a necessity denial
The plan document or formulary page the denial cites — you can request both in writing, and the appeal quotes them back
BMI history and weight-related conditions from your chart. Wegovy and Zepbound labels cover adults with BMI ≥30, or ≥27 with at least one weight-related condition — common FDA-labeled adult indications, not a universal plan coverage standard
For the pivot: the separately diagnosed condition on file — Type 2 diabetes labs, cardiovascular disease history, or a sleep study — plus a prescriber statement tying the prescription to that FDA-labeled indication
Records of drugs already tried, failed, or not tolerated — this answers step-therapy and “try a cheaper drug first” criteria
Honest odds: in 2024 ACA Marketplace data (KFF), fewer than 1% of denied in-network claims were formally appealed — and of the appeals that were filed, about 1 in 3 ended with the denial overturned internally. Those are population numbers, not a prediction for your case — and a pure plan-design exclusion with no separate covered indication sits at the weak end of that range. Outcomes depend on your plan, denial type, and documentation. Nobody can promise your appeal will win — anyone who does is selling something.
Questions
Weight-loss coverage questions, answered straight
My plan says weight-loss drugs are excluded — is appealing pointless?
Not automatically, but it is the hardest starting position, and we won’t pretend otherwise. A written plan-design exclusion usually can’t be beaten by arguing medical necessity — the plan simply doesn’t buy that benefit. What can still change the outcome: a formulary-exception request (marketplace and other essential-health-benefit plans must decide standard requests within 72 hours under 45 CFR 156.122, and a denied exception can go to independent external review), or a documented condition covered under a separate FDA label — Type 2 diabetes, established cardiovascular disease, or moderate-to-severe obstructive sleep apnea. If none of those apply to you, the case is genuinely weak, and Lysco’s free first read will say so plainly rather than sell you an appeal that isn’t worth sending.
Which conditions can reframe a “weight loss” claim?
Three documented conditions map to separately FDA-labeled indications: Type 2 diabetes (Ozempic and Mounjaro are labeled for it), established cardiovascular disease (Wegovy has a March 2024 indication to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight), and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound’s December 2024 indication). Each only helps if you actually meet the label criteria and your prescriber documents it — whether any indication applies to you is a decision for you and your doctor.
Does Medicare cover Wegovy or Zepbound for weight loss?
By statute, Medicare Part D and Medicare Advantage cannot cover GLP-1s for weight loss — weight-loss drugs are excluded from Part D. The narrow exception is a short-term CMS demonstration (the Medicare GLP-1 Bridge) running July 1, 2026 through December 31, 2027, offering eligible Part D beneficiaries weight-management GLP-1s at roughly $50 a month. It excludes people with Type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH, because those diagnoses have other coverage pathways, and it operates outside the normal Part D flow — it is not blanket Medicare coverage. Where Medicare deadlines do apply, note they can be short: Part D appeal windows can be 60 days.
How much does Lysco cost?
Your first read is free — upload the denial and see which denial type you have and whether a real path exists. If you proceed, it is a flat $9 to unlock the full ready-to-sign appeal and submission instructions. No subscription, no credit card to start. You review, sign, and send it yourself — Lysco never contacts your insurer.
Find out which denial you actually have — free
Your first read is free — including an honest “this one is weak” when that’s the truth. 30 seconds to upload. No credit card needed.
Check my denialEncrypted in transit and at rest · Access controlled · Delete anytime
Lysco is an informational tool — not a law firm, medical provider, or licensed patient advocate. We don’t prescribe or recommend medications; whether any indication applies to you is a decision for you and your doctor. Appeal outcomes vary by plan, diagnosis, documentation, and circumstances. This page is not medical or legal advice. All drug names are trademarks of their respective owners.